ARTICLE | Clinical News
SP-333: Phase II data
December 8, 2014 8:00 AM UTC
Top-line data from a double-blind Phase II trial in 289 patients with OIC taking opioid analgesics for chronic, non-cancer pain for =3 months showed that once-daily 3 and 6 mg oral SP-333 for 4 weeks ...